Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELZ NASDAQ:CLSD NASDAQ:ITRM NASDAQ:RNXT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELZCreative Medical Technology$3.18+0.6%$2.91$1.69▼$6.90$8.15M2.04165,328 shs25,502 shsCLSDClearside Biomedical$0.37-5.1%$0.57$0.29▼$1.65$30.42M2.08510,238 shs1.52 million shsITRMIterum Therapeutics$0.68-2.2%$0.85$0.65▼$3.02$30.90M2.851.05 million shs898,752 shsRNXTRenovoRx$0.96+1.3%$1.20$0.75▼$1.69$34.73M1.26233,952 shs218,794 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELZCreative Medical Technology+0.63%-0.31%+15.64%+45.21%-2.45%CLSDClearside Biomedical-5.14%-9.75%-18.33%-51.64%-63.25%ITRMIterum Therapeutics-2.20%-9.03%-9.64%-32.99%-38.47%RNXTRenovoRx+1.31%+2.10%-20.00%-29.15%-4.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCELZCreative Medical Technology1.2379 of 5 stars0.05.00.00.03.30.00.6CLSDClearside Biomedical2.6261 of 5 stars4.13.00.00.03.50.00.0ITRMIterum Therapeutics2.5439 of 5 stars3.53.00.00.03.31.70.0RNXTRenovoRx3.0885 of 5 stars3.55.00.00.03.21.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELZCreative Medical Technology 2.00HoldN/AN/ACLSDClearside Biomedical 2.17Hold$4.201,042.86% UpsideITRMIterum Therapeutics 3.00Buy$9.001,229.79% UpsideRNXTRenovoRx 3.00Buy$7.50681.25% UpsideCurrent Analyst Ratings BreakdownLatest CELZ, RNXT, ITRM, and CLSD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025RNXTRenovoRxAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.50 ➝ $12.008/12/2025CELZCreative Medical TechnologyZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold7/18/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$5.007/18/2025CLSDClearside BiomedicalChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral7/18/2025CLSDClearside BiomedicalStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$2.007/17/2025CLSDClearside BiomedicalJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/17/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold$3.006/5/2025RNXTRenovoRxAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $11.50(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELZCreative Medical Technology$10K820.44N/AN/A$2.65 per share1.20CLSDClearside Biomedical$1.66M17.38N/AN/A($0.62) per share-0.59ITRMIterum TherapeuticsN/AN/AN/AN/A($0.09) per shareN/ARNXTRenovoRx$40K879.60N/AN/A$0.29 per share3.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELZCreative Medical Technology-$5.49M-$3.18N/AN/AN/AN/A-82.99%-79.49%11/14/2025 (Estimated)CLSDClearside Biomedical-$34.35M-$0.37N/AN/AN/A-665.19%N/A-124.15%11/11/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.85N/A∞N/AN/AN/A-65.01%11/13/2025 (Estimated)RNXTRenovoRx-$8.81M-$0.38N/AN/AN/AN/A-120.68%-89.23%11/12/2025 (Estimated)Latest CELZ, RNXT, ITRM, and CLSD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RNXTRenovoRx-$0.08-$0.08N/A-$0.08$0.25 million$0.42 million8/8/2025Q2 2025CELZCreative Medical Technology-$0.63-$0.48+$0.15-$0.48N/AN/A8/8/2025Q2 2025CLSDClearside Biomedical-$0.12-$0.06+$0.06-$0.06$0.50 million$0.49 million8/5/2025Q2 2025ITRMIterum Therapeutics-$0.13-$0.16-$0.03-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCELZCreative Medical TechnologyN/AN/AN/AN/AN/ACLSDClearside BiomedicalN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ARNXTRenovoRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELZCreative Medical TechnologyN/A23.8623.86CLSDClearside BiomedicalN/A3.873.87ITRMIterum TherapeuticsN/A2.692.52RNXTRenovoRxN/A8.618.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELZCreative Medical Technology1.42%CLSDClearside Biomedical18.75%ITRMIterum Therapeutics9.21%RNXTRenovoRx3.10%Insider OwnershipCompanyInsider OwnershipCELZCreative Medical Technology2.80%CLSDClearside Biomedical6.70%ITRMIterum Therapeutics2.40%RNXTRenovoRx9.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELZCreative Medical Technology52.58 million2.51 millionNot OptionableCLSDClearside Biomedical3078.51 million73.25 millionOptionableITRMIterum Therapeutics1044.66 million43.59 millionNot OptionableRNXTRenovoRx636.65 million33.30 millionNot OptionableCELZ, RNXT, ITRM, and CLSD HeadlinesRecent News About These CompaniesRenovoRx (NASDAQ:RNXT) Upgraded by Wall Street Zen to Hold RatingAugust 23, 2025 | americanbankingnews.comDiscovering the Next Wave of Biotech Innovation (MDCX, RNXT, JSPR, LSB)August 22, 2025 | theglobeandmail.comFY2025 EPS Estimates for RenovoRx Increased by HC WainwrightAugust 22, 2025 | americanbankingnews.comFY2027 EPS Estimates for RenovoRx Cut by HC WainwrightAugust 21, 2025 | americanbankingnews.comRenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City, September 8-10, 2025August 20, 2025 | finance.yahoo.comRenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025August 20, 2025 | businesswire.comRenovoRx, Inc. (NASDAQ:RNXT) Q2 2025 Earnings Call TranscriptAugust 19, 2025 | msn.comRenovoRx Revenue Jumps 28 Percent in Q2August 14, 2025 | theglobeandmail.comRenovoRx Reports Strong Q2 2025 Revenue GrowthAugust 14, 2025 | msn.comRenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue EstimatesAugust 14, 2025 | zacks.comRenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data ReviewAugust 14, 2025 | businesswire.comRenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership HireAugust 6, 2025 | globenewswire.comRenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid TumorsJuly 28, 2025 | finance.yahoo.comRenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ETJuly 14, 2025 | businesswire.comInsider Buying: RenovoRx, Inc. (NASDAQ:RNXT) Insider Buys 21,000 Shares of StockJune 10, 2025 | insidertrades.comRenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 ResultsJune 6, 2025 | finance.yahoo.comAscendiant Capital relève l’objectif de cours de l’action RenovoRx à 11,50€June 5, 2025 | fr.investing.comEarnings call transcript: RenovoRx Q1 2025 revenue exceeds expectationsMay 17, 2025 | investing.comRenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comRenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ...May 16, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCELZ, RNXT, ITRM, and CLSD Company DescriptionsCreative Medical Technology NASDAQ:CELZ$3.18 +0.02 (+0.63%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$3.15 -0.03 (-0.91%) As of 08/29/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Clearside Biomedical NASDAQ:CLSD$0.37 -0.02 (-5.14%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.37 +0.00 (+0.14%) As of 08/29/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Iterum Therapeutics NASDAQ:ITRM$0.68 -0.02 (-2.20%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.70 +0.02 (+2.69%) As of 08/29/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.RenovoRx NASDAQ:RNXT$0.96 +0.01 (+1.31%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.98 +0.02 (+2.08%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
